Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 29;:
Authors: Poleg S, Golubchik P, Offen D, Weizman A
Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities of ASD. In this review we summarize the available pre-clinical and clinical data regarding the safety and effectiveness of medical cannabis, including CBD, in young ASD patients. Cannabidiol seems to be a candidate for the treatment of ASD. At present, however, there are no convincing pre-clinical or clinical data showing efficacy and safety of cannabinoid treatment in ASD patients.
PMID: 30171992 [PubMed – as supplied by publisher]
Source: Estudios sobre Cannabidiol (CBD)